Fedwatch: How Few i...
Health Care: Drugs
Amarin Corporation PLC (AMRN: NASDAQ)
$6.47 -0.13 | -1.97%
06/19/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 6.60 |
| 52 Week High | 15.96 |
| 52 Week Low | 6.25 |
| Avg. Daily Vol. (Mil) | 3.83 |
| Beta (3 year) | 1.26 |
| Share Related Items | |
| Mkt Cap (Mil) | 992.06 |
| Shares Out (Mil) | 150.31 |
| Float (Mil) | 0.00 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.80 |
| Current Ratio | 5.70 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 423.78 |
| Price/Book | 0.00 |
| Price/Cash Flow | -3.60 |
| Per Share Data | |
| Earnings | -0.26 |
| Sales | 0.02 |
| Book Value | 0.00 |
| Cash Flow | -1.85 |
| Business Summary | |
|---|---|
| Amarin Corporation PLC is a biopharmaceutical company that commercializes and develops therapeutics to improve cardiovascular health. | |
| General Information | |
| 2 Pembroke House
Upper Pembroke Street 28-32 Dublin, 2 |
|
| www.amarincorp.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 111 | |
| CEO: Joseph S. Zakrzewski | |
| Short Interest | |
| Current Month (Mil) | 24.92 |
| Previous Month (Mil) | 25.58 |
| Short Interest Ratio (Days) | 5.70 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -108.80 |
| Return on Investments | -164.00 |
| Profitability | |
| Gross Margin | 45.00 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with AMRN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Useralexr685
- ContributorDrugs Facing FDA Approval i...
- ContributorHigh Volume Technicals for ...
- ContributorBreakout Stocks Of The Week...
- UserHassan Portfolio
- Contributor4 Drug Stocks Facing FDA Ap...
- UserLividog
- ContributorStocks Rising On Unusual Vo...
- UserPharma
Latest AMRN Headlines from TheStreet
- 3 Drug Stocks Poised To Move As Bears Attack 06.19.13 | 05:06 pm
- Amarin: FDA Panel Date, Misplaced Hype For Fixed-Dose Combo 06.19.13 | 11:06 am
- Amarin Informed By FDA Of October 16th Advisory Committee Date In Connection With Supplemental New Drug Application (sNDA) For Vascepa(R) In The Treatment Of Patients With High Triglycerides (>200 Mg/dL And <500 Mg/dL) With Mixed Dyslipidemia 06.19.13 | 07:06 am
- As If Amarin Needs Another Worry, Here Comes A Vascepa FDA Panel 06.06.13 | 11:06 am
- June 14th Options Now Available For Amarin Corp Plc (AMRN) 06.06.13 | 10:06 am
- Amarin To Present At The Jefferies 2013 Global Healthcare Conference 05.30.13 | 04:05 pm
- June 7th Options Now Available For Amarin Corp Plc (AMRN) 05.30.13 | 11:05 am
- Amarin Announces Additional Effects Of Vascepa(R) On Lipoprotein Particle Concentration From The ANCHOR Study Presented At The National Lipid Association 2013 Annual Scientific Sessions 05.30.13 | 06:05 am
- Doc Claims SummerStreet's Amarin Report Is Inaccurate 05.29.13 | 07:05 am
- Big Pharma Wants Fish Oil After All, But At Half Amarin's Selling Price 05.28.13 | 09:05 am
Press Releases for AMRN
- Amarin To Present At The Deutsche Bank 26th Annual Healthcare Conference - PR Newswire 04.26.11 | 08:04 am
- Amarin's AMR101 Phase 3 ANCHOR Trial Meets All Primary And Secondary Endpoints With Statistically Significant Reductions In Triglycerides At Both 4 Gram And 2 Gram Doses And Statistically Significant Decrease In LDL-C - PR Newswire 04.18.11 | 02:04 am
- Phase 3 MARINE Trial Data To Be Presented In May At The National Lipid Association 2011 Annual Scientific Sessions - PR Newswire 04.05.11 | 08:04 am
- Amarin To Present At The 10th Annual Needham Healthcare Conference - PR Newswire 03.31.11 | 07:03 am
Partner Headlines for AMRN
- Bull, Bear, Or Indifferent: Profiting From Amarin's Latest - Seeking Alpha 06.11.13 | 09:06 am
- What Must Be In The Ideal Biopharmaceutical Portfolio? - Seeking Alpha 06.05.13 | 09:06 am
- Pre-Market Most Active for May 30, 2013 : NVE, CLWR, S, MTU, FB, BAC, NJ, EMC, VNR, QQQ, AMRN, FSLR - NASDAQ 05.30.13 | 12:05 pm
- Amarin & Celsion: Post-Earnings Roundup - Seeking Alpha 05.15.13 | 09:05 am
- Will Amarin’s Positive Test Result Impress These Top Institutional Shareholders? - Wall St. Cheat Sheet 04.08.13 | 01:04 pm
- Will Amarin’s Positive Test Result Impress These Top Institutional Shareholders? - Wall St. Cheat Sheet 04.08.13 | 01:04 pm
- 4 Healthcare Stock Stories for Monday Investment Wellness - Wall St. Cheat Sheet 04.01.13 | 02:04 am
- 4 Healthcare Stock Stories for Monday Investment Wellness - Wall St. Cheat Sheet 04.01.13 | 02:04 am
- Trius Therapeutics: New MSRA Treatment Could Bring Billions In Revenues - Seeking Alpha 03.05.13 | 09:03 am
- Stock Watch Tuesday, 8 January - Seeking Alpha 01.08.13 | 09:01 am
